Journal
CURRENT DRUG TARGETS
Volume 21, Issue 12, Pages 1194-1200Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450121666200428101738
Keywords
Anti-VEGF; conbercept; brolucizumab; port delivery system; ranibizumab; abicipar pegol; faricimab
Categories
Ask authors/readers for more resources
This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
